# Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

> **NCT02267707** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 1 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Cholestasis

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02267707
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-27
- **Primary completion:** 2016-02-10
- **Final completion:** 2016-02-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study population more infrequent than estimated. No study-related safety issues and no safety concerns were identified for the study.
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267707, "Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02267707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*